Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...
Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...
MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.
Medpage Today on MSN26d
How Progressive Multiple Sclerosis Differs From Relapsing-Remitting MSPPMS typically includes a steady loss of function from the onset of symptoms. The vast majority of people with MS receive ...
A REIT's debt levels, interest rate issues and financial performance are important factors when deciding which DST with a 721 ...
Other MS patients, a minority, have a form of the disease that features gradually increasing progressive disability from onset—so-called primary progressive MS (PPMS). While effective disease ...
China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback